Pipeline

MMB pipeline addresses significant medically unmet needs in immuno-oncology by directly targeting T cells, immune checkpoints and tumor micro-environment.

MediMabBio’s pipelines include first-in-class antibody immunotherapies, which target an immune checkpoint inhibitor (ICI) and antagonistic or agonistic activity on the signaling receptor in different sets of immune cells. This is expected to induce anti-tumor immunity by stimulating effector T cells and inhibiting regulatory T cell activity. In order to modulate tumor microenvironment with optimized specificity and functionality, the company focuses on generating Neokine-tethered immunotherapeutic antibody, which has been developed through computational modelling and well-established MMB screening system.

Category Program Therapeutic Indication Development stage
Target Discovery Hit Optimization Lead Optimization Pre-clinical IND Clinical
Immune Checkpoint Antibody MMB-101 Immuno Oncology
MMB-102 Immuno Oncology
MMB-103 Immuno Oncology
Immuno-cytokine MMB-201 Immuno Oncology
Program Therapeutic Indication Development stage
Discovery Development Pre-/Clinical
MMB-101 Immuno Oncology
MMB-102 Immuno Oncology
MMB-103 Immuno Oncology
MMB-201 Immuno Oncology
Program Development stage
Discovery Development Pre-/Clinical
MMB-101
MMB-102
MMB-103
MMB-201